Lello Stefano, Capozzi Anna, Scambia Giovanni
Department of Woman and Child Health, Policlinico Gemelli Foundation, Largo Agostino Gemelli, Roma, Italy.
Int J Endocrinol. 2017;2017:5064725. doi: 10.1155/2017/5064725. Epub 2017 Dec 5.
The tissue-selective estrogen complex (TSEC) pairs conjugated estrogens (CE) with a selective estrogen receptor modulator (SERM), bazedoxifene acetate (BZA). A 2-year treatment with the TSEC improved vasomotor symptoms, quality of life, and vaginal atrophy in healthy postmenopausal women. In addition, the TSEC prevented vertebral and hip bone loss without increasing mammographic density, breast tenderness, the risk of myocardial infarction, stroke, or venous thromboembolism. Finally, the BZA 20 mg/CE 0.45 mg dose did not increase the risk of endometrial hyperplasia. Based on these findings, the TSEC can be considered as a first-line treatment for symptomatic postmenopausal women.
组织选择性雌激素复合物（TSEC）将共轭雌激素（CE）与选择性雌激素受体调节剂（SERM）醋酸巴多昔芬（BZA）相结合。对健康绝经后女性进行为期两年的TSEC治疗可改善血管舒缩症状、生活质量及阴道萎缩。此外，TSEC可预防椎体和髋部骨质流失，且不会增加乳房X线密度、乳房压痛、心肌梗死、中风或静脉血栓栓塞的风险。最后，20毫克BZA/0.45毫克CE的剂量不会增加子宫内膜增生的风险。基于这些发现，TSEC可被视为有症状绝经后女性的一线治疗方法。
